TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01289704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TreSPE
Description: 1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls.
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo tablets
Description: Oral tablets
Study: NCT03557554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
Study: NCT03518931

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fitness testing
Description: The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
Study: NCT01016561

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intracavitary balloon brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT01600118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: 1000 impulses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No extracorporeal shockwave
Description: 0 impulses, acoustic effect
Study: NCT01289704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TreSPE
Description: 1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls.
Study: NCT02769481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 2, 4 or 6 mg, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Glimepiride
Description: inactive capsules to match active comparator glimepiride
Study: NCT01289704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPE
Description: 1. Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~2. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~3. Proprioceptive and postural kinesitherapy according to the neurocognitive method.~4. Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls.
Study: NCT02451930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT03639675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (EYLEA, BAY86-5321)
Description: 2 mg (0.05 mL), Intravitreal injection (IVT), single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical IOP-lowering drugs
Description: A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
Study: NCT04502667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 1000U or 2000U every 24 hours orally
Study: NCT04372511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binaural Beats
Description: Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Oral tablets
Study: NCT04007432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse oxymeter
Description: Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
Study: NCT04353414

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transmuscular Quadratus Lumborum Block
Description: Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular injection
Description: Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular injection
Description: Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
Study: NCT03642743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative follow up appointment
Description: Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative follow up appointment
Description: Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
Study: NCT04425824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab combine with Rituximab
Description: Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).
Study: NCT02730520

Intervention type: OTHER
Intervention: Retrospective analysis of patient files
Description: The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
Study: NCT01226043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous
Study: NCT02312921

Intervention type: OTHER
Intervention: PREDICT
Description: Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
Study: NCT01851915

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 14 sessions psychological treatment for depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: 14 sessions psychological treatment for depression
Study: NCT03267732

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone
Study: NCT01244945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Description: L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo tabs identical in form, taste and consistency to active tabs
Study: NCT02103049

Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe
Description: Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
Study: NCT02296944

Intervention type: OTHER
Intervention: Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery

Intervention type: OTHER
Intervention: Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery

Intervention type: OTHER
Intervention: Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery

Intervention type: OTHER
Intervention: Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
Study: NCT02715479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS955176
Description: BMS955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS955176
Description: BMS955176
Study: NCT06202456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huazhi Rougan granule
Description: Huazhi Rougan granule
Study: NCT02386969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS then sham rTMS
Description: A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham rTMS then active rTMS
Description: A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
Study: NCT04017247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intermittent oxytocin Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Continous oxytocin Infusion for 16 hours
Study: NCT03622359

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT/CT perfusion imaging
Description: Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT/CT perfusion imaging
Description: Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT perfusion imaging
Description: Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT perfusion imaging
Description: Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
Study: NCT01149811

Intervention type: DRUG
Intervention: Fipamezole ODT
Description: Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.

Intervention type: DRUG
Intervention: Fipamezole ODT Cohort 2
Description: Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
Study: NCT03949985

Intervention type: OTHER
Intervention: Tests of biological hemostatic profile associated with contraceptives
Description: Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)

Intervention type: OTHER
Intervention: Tests of biological hemostatic profile associated with contraceptives
Description: Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
Study: NCT01819376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook Status Update
Study: NCT02482207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life style modification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style modification
Study: NCT02435069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Response - NS and USP Glycerin - First Intervention
Description: This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effectiveness - NS and USP Glycerin - Second Intervention
Description: To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
Study: NCT03979430

Intervention type: OTHER
Group type: OTHER
Intervention: Home spirometry
Description: Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
Study: NCT00843726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1 stereotactic body radiation therapy
Description: Patients undergo 1 high-dose fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm II stereotactic body radiation therapy
Description: Patients undergo 3 high-dose fractions
Study: NCT00800748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
Study: NCT00072176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00900198

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
Study: NCT04349436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1, intra-tumoral injection, oncolytic virus
Description: Genetically modified herpes simplex type 1 virus
Study: NCT03475693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Description: 400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zofran ODT 4 MG Disintegrating Oral Tablet
Description: Given once in the Emergency department

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT 4 MG Disintegrating Oral Tablet
Description: Given once in the Emergency department